Episode Details
Back to Episodes
"Landmark Deal Slashes GLP-1 Drug Prices for Millions"
Published 4 months ago
Description
You’re listening to News Today: Global News — Every city. Every story. Every day. I’m Marcus Ellery, your AI correspondent, and this report is brought to you by Quiet Please AI.
This evening, a major announcement from Washington is set to alter the course of healthcare for millions of Americans, with ripple effects likely to be felt well beyond U.S. borders. According to ABC News, the Trump administration has secured a landmark agreement with pharmaceutical leaders Novo Nordisk and Eli Lilly, heralding a new chapter in drug affordability and access. These deals, reached after months of negotiation, will dramatically lower the prices of widely used GLP-1 drugs—medications at the center of the global conversation around obesity, diabetes, and related chronic illnesses. As reported by ABC News, these medications, most notably including treatment options like Wegovy, have rapidly grown in demand around the world for their ability to address not just weight loss but a spectrum of metabolic and cardiovascular conditions.
Senior administration officials revealed that once the public-private partnership, known as TrumpRx, launches, eligible patients will see their monthly cost fall to about $350 for the injectable version of these drugs—nearly a third lower than current average out-of-pocket prices. This cost is slated to drop even further, down to $250, over the next two years, especially for individuals paying without insurance. For those awaiting oral versions, both drugmakers confirmed they are set to introduce daily pill alternatives as soon as next year, pending final FDA approval, with introductory prices expected at $150 for early doses.
This story is especially significant for Medicare beneficiaries. For the first time, people living with severe obesity—defined as having a body mass index over 35—will qualify for these medications with a flat $50 co-pay, potentially as early as mid-2026. While the announcement stops short of providing broad coverage for all overweight or obese Americans on public insurance, it marks a substantial policy breakthrough. According to remarks by Eli Lilly’s CEO David Ricks, the deal represents “a pivotal moment in U.S. healthcare policy,” underlining the collaborative approach between government and industry to expand access and contain costs.
Novo Nordisk echoed that sentiment in its statement, emphasizing that this pricing alignment for semaglutide—the key GLP-1 molecule—will enable more equitable patient access. Importantly, this move may set a precedent, with other countries watching how these efforts to widen access while curbing costs play out, at a time when obesity and diabetes are rising sharply in developed and developing nations alike.
As the world grapples with the challenges of chronic disease, affordability, and innovation, tonight’s agreement is more than domestic news. It’s a signal of what creative partnerships can accomplish under the pressure of global health priorities. Listeners, as new details unfold and reactions come in from both industry and advocacy groups, we’ll keep you updated.
Thank you for tuning in to News Today: Global News. Subscribe to stay informed on every city, every story, every day. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/4mhVDh7
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
This evening, a major announcement from Washington is set to alter the course of healthcare for millions of Americans, with ripple effects likely to be felt well beyond U.S. borders. According to ABC News, the Trump administration has secured a landmark agreement with pharmaceutical leaders Novo Nordisk and Eli Lilly, heralding a new chapter in drug affordability and access. These deals, reached after months of negotiation, will dramatically lower the prices of widely used GLP-1 drugs—medications at the center of the global conversation around obesity, diabetes, and related chronic illnesses. As reported by ABC News, these medications, most notably including treatment options like Wegovy, have rapidly grown in demand around the world for their ability to address not just weight loss but a spectrum of metabolic and cardiovascular conditions.
Senior administration officials revealed that once the public-private partnership, known as TrumpRx, launches, eligible patients will see their monthly cost fall to about $350 for the injectable version of these drugs—nearly a third lower than current average out-of-pocket prices. This cost is slated to drop even further, down to $250, over the next two years, especially for individuals paying without insurance. For those awaiting oral versions, both drugmakers confirmed they are set to introduce daily pill alternatives as soon as next year, pending final FDA approval, with introductory prices expected at $150 for early doses.
This story is especially significant for Medicare beneficiaries. For the first time, people living with severe obesity—defined as having a body mass index over 35—will qualify for these medications with a flat $50 co-pay, potentially as early as mid-2026. While the announcement stops short of providing broad coverage for all overweight or obese Americans on public insurance, it marks a substantial policy breakthrough. According to remarks by Eli Lilly’s CEO David Ricks, the deal represents “a pivotal moment in U.S. healthcare policy,” underlining the collaborative approach between government and industry to expand access and contain costs.
Novo Nordisk echoed that sentiment in its statement, emphasizing that this pricing alignment for semaglutide—the key GLP-1 molecule—will enable more equitable patient access. Importantly, this move may set a precedent, with other countries watching how these efforts to widen access while curbing costs play out, at a time when obesity and diabetes are rising sharply in developed and developing nations alike.
As the world grapples with the challenges of chronic disease, affordability, and innovation, tonight’s agreement is more than domestic news. It’s a signal of what creative partnerships can accomplish under the pressure of global health priorities. Listeners, as new details unfold and reactions come in from both industry and advocacy groups, we’ll keep you updated.
Thank you for tuning in to News Today: Global News. Subscribe to stay informed on every city, every story, every day. This has been a quiet please production, for more check out quiet please dot ai.
Some great Deals https://amzn.to/4mhVDh7
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI